[
  {
    "ts": "2026-01-21T12:11:01+00:00",
    "headline": "Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best undervalued wide moat stocks. On January 13, 2026, an announcement came regarding the Ro and Amgen Inc. (NASDAQ:AMGN) collaboration. Ro, a U.S. telehealth firm, alongside Amgen, aims to investigate barriers patients face in accessing obesity treatments, including GLP-1 drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s […]",
    "url": "https://finance.yahoo.com/news/amgen-amgn-expands-obesity-strategy-121101061.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "824c792e-c545-3d09-8882-66f25c349abb",
      "content": {
        "id": "824c792e-c545-3d09-8882-66f25c349abb",
        "contentType": "STORY",
        "title": "Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies",
        "description": "",
        "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best undervalued wide moat stocks. On January 13, 2026, an announcement came regarding the Ro and Amgen Inc. (NASDAQ:AMGN) collaboration. Ro, a U.S. telehealth firm, alongside Amgen, aims to investigate barriers patients face in accessing obesity treatments, including GLP-1 drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s […]",
        "pubDate": "2026-01-21T12:11:01Z",
        "displayTime": "2026-01-21T12:11:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/89c0b31c8a49a4b2c6733fddd0910df8",
          "originalWidth": 4069,
          "originalHeight": 2713,
          "caption": "Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sunxx6hqXfBWKrzfL3htQg--~B/aD0yNzEzO3c9NDA2OTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/89c0b31c8a49a4b2c6733fddd0910df8.cf.webp",
              "width": 4069,
              "height": 2713,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2LdiLb4t.zgVLda0bwZNgg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/89c0b31c8a49a4b2c6733fddd0910df8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-expands-obesity-strategy-121101061.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-amgn-expands-obesity-strategy-121101061.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T12:10:45+00:00",
    "headline": "AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug […]",
    "url": "https://finance.yahoo.com/news/abbvie-abbv-looks-deepen-push-121045476.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8d42e3f4-ae24-3a22-b2ad-17de10ae72cb",
      "content": {
        "id": "8d42e3f4-ae24-3a22-b2ad-17de10ae72cb",
        "contentType": "STORY",
        "title": "AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market",
        "description": "",
        "summary": "AbbVie Inc. (NYSE:ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in. On January 14, 2026, Reuters reported that AbbVie Inc. (NYSE:ABBV) is looking to deepen its push into the rapidly growing obesity-treatment market, outlining its plans at the JPMorgan Healthcare Conference. The company’s plans center on GUBamy, an amylin-mimetic weight-loss drug […]",
        "pubDate": "2026-01-21T12:10:45Z",
        "displayTime": "2026-01-21T12:10:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ae3aff8170c32ab72e21b7d307dd751f",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "AbbVie (ABBV) Looks to Deepen Its Push Into Rapidly Growing Obesity-Treatment Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QJoE63tFdMpnnrAbqprcaw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/ae3aff8170c32ab72e21b7d307dd751f.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gi43WiQpLk0J.NMrpOdajw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ae3aff8170c32ab72e21b7d307dd751f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-looks-deepen-push-121045476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-abbv-looks-deepen-push-121045476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "GUBRA.CO"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T14:02:00+00:00",
    "headline": "Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference",
    "summary": "SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.",
    "url": "https://finance.yahoo.com/news/biocom-announces-powerhouse-keynote-panel-140200849.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b028eac3-64bb-3971-aaca-c715dc8f6d5f",
      "content": {
        "id": "b028eac3-64bb-3971-aaca-c715dc8f6d5f",
        "contentType": "STORY",
        "title": "Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference",
        "description": "",
        "summary": "SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.",
        "pubDate": "2026-01-21T14:02:00Z",
        "displayTime": "2026-01-21T14:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/cd0edc9343dd2e6691c3cef19f8e87ed",
          "originalWidth": 1000,
          "originalHeight": 328,
          "caption": "Biocom’s Global Partnering & Investor Conference brings together over 500 investors and senior executives, including CEOs and heads of business development, biotech, and research and development from leading pharmaceutical, biotech and research organizations from over 20 countries. This prestigious conference features panel discussions, one-on-one partnering meetings, presentations from small companies and leading research institutions, and endless networking opportunities. Learn more and register: https://www.biocomglobalpartnering.org.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gA7YWJhDU8zLmyCnZeuToQ--~B/aD0zMjg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cd0edc9343dd2e6691c3cef19f8e87ed.cf.webp",
              "width": 1000,
              "height": 328,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zJiVOJSw7_VJMxhZmA2BmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cd0edc9343dd2e6691c3cef19f8e87ed.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biocom-announces-powerhouse-keynote-panel-140200849.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biocom-announces-powerhouse-keynote-panel-140200849.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T15:00:00+00:00",
    "headline": "Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement",
    "summary": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
    "url": "https://finance.yahoo.com/news/lilly-confirms-date-conference-call-150000111.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "70933431-2c73-3f60-bf61-e2ac33b417cd",
      "content": {
        "id": "70933431-2c73-3f60-bf61-e2ac33b417cd",
        "contentType": "STORY",
        "title": "Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
        "pubDate": "2026-01-21T15:00:00Z",
        "displayTime": "2026-01-21T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-confirms-date-conference-call-150000111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-confirms-date-conference-call-150000111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T12:57:00+00:00",
    "headline": "Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention",
    "summary": "TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.",
    "url": "https://finance.yahoo.com/news/tempus-ais-key-2025-milestones-125700580.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e82b2c24-96b2-3632-8160-5e3228321b00",
      "content": {
        "id": "e82b2c24-96b2-3632-8160-5e3228321b00",
        "contentType": "STORY",
        "title": "Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention",
        "description": "",
        "summary": "TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.",
        "pubDate": "2026-01-21T12:57:00Z",
        "displayTime": "2026-01-21T12:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ais-key-2025-milestones-125700580.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ais-key-2025-milestones-125700580.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "WHWK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]